Role of oral iron in the management of long-term hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 4, 2007, Pages 688-693

  Lenga, Ilan ^a   Lok, Charmaine ^b   Marticorena, Rosa ^c   Hunter, Joyce ^c   Dacouris, Niki ^c   Goldstein, Marc ^c  

^a LAKERIDGE HEALTH CORPORATION   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

AGED; ARTICLE; CROSS-SECTIONAL STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME;

ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; CROSS-SECTIONAL STUDIES; FEASIBILITY STUDIES; FEMALE; HUMANS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS;

EID: 34548817601     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00420107     Document Type: Article

References (30)

1. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35: 712-716, 1989
2. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78, 1987
3. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41-46, 1995
4. MacDougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine EG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996
5. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998
6. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30[Suppl 3]: S192-S240, 1997
7. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: Update 2006. Am J Kidney Dis 47[Suppl 3]: S11-145, 2006
8. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH: The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease. Clin J Am Soc Nephrol 1: S9-S18, 2006
9. Coyne DW, Kapolan T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; the DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis patients Response to IV iron with Elevated ferritin (DRIVE) study. J Am Soc Nephrol 18: 975-984, 2007
10. Strippoli GF, Craig JC, Manno C, Schena FP: Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15: 3154-3165, 2004
11. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
12. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
13. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, Gorman J, Taylor DW: Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 4: 1809-1813, 1994
14. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005
15. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469-475, 2002
16. Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N: Pure red-cell aplasia and epoetin therapy. N Engl J Med 351: 1403-1408, 2004
17. Sullivan JL: Iron therapy and cardiovascular disease. Kidney Int Suppl 69: S135-S137, 1999
18. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V London GM: Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end stage renal disease. Circulation 106: 2212-2217, 2002
19. Stevens RG, Graubard BJ, Micozzi MS, Neriishi K, Blumberg BS: Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 56: 364-369, 1994
20. Weinberg ED: Iron therapy and cancer. Kidney Int Suppl 69: S131-S134, 1999
21. Weinberg ED: Iron and infection. Microbiol Rev 42: 45-66, 1978
22. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in hemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14: 2680-2687, 1999
23. Roob JM, Khoschsorur G, Tiran A Horina JH, Holzer H, Winklhofer-Roob BM: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11: 539-549, 2000
24. Tovbin D, Mazor D, Vorobiov M, Chiamovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 40: 1005-1012, 2002
25. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular disease: The role of oxidant stress. Circ Res 87: 840-844, 2000
26. Stocker R, Keaney JF Jr: Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478, 2004
27. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340: 115-126, 1999
28. Sempos CT, Looker AC, Gillum R Makuc DM: Body iron stores and the risk of coronary heart disease. N Engl J Med 330: 1119-1124, 1994
29. de Valk B, Marx JJ: Iron, atherosclerosis and ischemic heart disease. Arch Intern Med 160: 241-242, 2000
30. Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, Weiss G: Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll Cardiol 40: 2189-2194, 2002